Reply to the Comment on ‘Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Adenocarcinoma After Folfirinox Failure: An AGEO Prospective Multicentre Cohort’

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2016.70
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Neoadjuvant Treatment With Gemcitabine Plus Nab-Paclitaxel Versus Surgery First for Pancreatic Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

Comparative Effectiveness of Nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

Advances in Therapy
MedicinePharmacology
2018English

A Granulocyte Colony-Stimulating Factor-Producing Pancreatic Adenocarcinoma Treated With Nab-Paclitaxel Plus Gemcitabine Chemotherapy

Suizo
2018English

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2017English

NeoadjuvantNab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX

Anticancer Research
MedicineCancer ResearchOncology
2018English

Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy